Solnatide

Drug Profile

Solnatide

Alternative Names: AP-301

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APEPTICO Forschung und Entwicklung
  • Class Peptides
  • Mechanism of Action Inflammasome inhibitors; P38 mitogen-activated protein kinase inhibitors; Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury; Acute lung injury; Pulmonary oedema; Pseudohypoaldosteronism
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Pulmonary oedema; Reperfusion injury
  • Preclinical Pseudohypoaldosteronism

Most Recent Events

  • 27 Feb 2018 Apeptico initiates enrolment in a phase II trial for Pulmonary oedema in patients with acute respiratory distress syndrome in Austria (EudraCT2017-003855-47)
  • 15 Dec 2016 Pharmacodynamics data from a preclinical trial in Pulmonary oedema released by Apeptico
  • 02 Dec 2016 Solnatide licensed to Apeptico in various European markets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top